Psyence Biomed Announces Phase IIb Clinical Trial Listing On The Australian New Zealand Clinical Trials Registry
Psyence Biomed Announces Phase IIb Clinical Trial Listing On The Australian New Zealand Clinical Trials Registry
Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry ("ANZCTR"), under registration number 12624000449538p.
Psyence Biomedical Ltd（納斯達克股票代碼：PBM）（“Psyence Biomed” 或 “公司”）今天宣佈，其即將對姑息治療背景下晚期癌症診斷患有調節障礙的患者進行自然衍生的迷幻藥的IIb期臨床試驗的細節已列入澳大利亞新西蘭臨床試驗登記處（“ANZCTR”），註冊號爲12624000449538p。
The randomized, double-blind, placebo-controlled Phase IIb study will test three doses (25mg, 10mg and 1mg) of nature-derived psilocybin in 84 patients in conjunction with psychotherapy. Psyence Biomed anticipates enrolling the first subject in the second quarter of 2024 and expects the primary endpoint results to be available in 2025.
這項隨機、雙盲、安慰劑對照的IIb期研究將在84名患者中測試三劑量（25mg、10mg和1mg）天然來源的迷幻藥，同時進行心理治療。Psyence Biomed預計將在2024年第二季度招收第一名受試者，並預計主要終點結果將在2025年公佈。
"The listing for our Phase IIb clinical trial on ANZCTR reflects the meaningful progress that we are making in the development of a safe and effective psilocybin-based treatment for the roughly 19% of patients who suffer from Adjustment Disorder following an advanced cancer diagnosis1, with a focus on Palliative Care," said Neil Maresky, MD, Chief Executive Officer of Psyence Biomed. "Working with our partners, Fluence and iNGENū, we look forward to screening the first patients for this important trial in the coming weeks and efficiently advancing it through to topline data next year."
Psyence Biomed首席執行官尼爾·馬雷斯基醫學博士表示：“我們在ANZCTR的IIb期臨床試驗的清單反映了我們在爲大約19％的晚期癌症診斷後患有適應障礙的患者1開發安全有效的迷幻藥基礎治療方面取得了有意義的進展，重點是姑息治療。”“與我們的合作伙伴Fluence和ingenu合作，我們期待在未來幾周內篩查這項重要試驗的首批患者，並有效地將其推向明年的頭號數據。”
More information can be found on the ANZCTR website: 12624000449538p.
更多信息可以在ANZCTR網站上找到：12624000449538p。
譯文內容由第三人軟體翻譯。